Medical news
-
Letter to WFH Humanitarian Aid recipient countries
Since December 2019, COVID-19 has become an ongoing public health issue which has affected everyone in the world—and the bleeding disorders community has been particularly...
-
Event: WFH webinar on bleeding disorders and COVID-19
On Thursday, April 9th, at 10:00 am EST, the World Federation of Hemophilia (WFH) will host a 60-minute webinar for the bleeding disorders community to...
-
Specific Risks of COVID-19 to the Bleeding Disorders Community
WFH COVID-19 Task Force: Assad Haffar, Cedric Hermans, Barbara Konkle, Brian O’Mahony, David Page, Flora Peyvandi, Steve Pipe, Mark Skinner and Radek Kaczmarek and Glenn...
-
COVID-19 (coronavirus disease 2019) pandemic caused by SARS-CoV-2: practical recommendations for people with hemophilia
From the World Federation of Hemophilia Medical Advisory Board (MAB)* and the WFH Coagulation Product Safety, Supply, and Access (CPSSA) Committee.
-
World Federation of Hemophilia Statement: Update to COVID-19
Since December 2019 the coronavirus, now known as COVID-19, has become an ongoing public health issue. The World Federation of Hemophilia (WFH) is committed to...
-
WFH statement on outbreak of novel coronavirus (2019-nCoV)
Introduction On December 31, 2019, Chinese health authorities identified a new (or novel) coronavirus (referred to as 2019-nCoV) through a series of reported cases of...
-
Gene therapy in hemophilia a hot topic at the WFH Global Forum 2019
Gene therapy in hemophilia featured heavily at the World Federation of Hemophilia Global Forum held in Montréal November 13 to 14, 2019. Glenn Pierce, MD,...
-
Now available: The WFH Report on the Annual Global Survey 2018
The World Federation of Hemophilia (WFH) Report on the Annual Global Survey (AGS) 2018 is now available! This survey provides a global snapshot of the...
-
WFH holds webinar titled Updated Estimates of Prevalence and Prevalence at Birth of Hemophilia
The World Federation of Hemophilia (WFH) has spearheaded a scientific study updating the prevalence of hemophilia to higher numbers than previously estimated and providing, for...
-
A WFH Advisory on Particulate Matter in Emicizumab (HEMLIBRA) and Other Biologic Agents
Since the development of intravenous therapies, the presence of particulate matter in injectable drugs has been a concern for clinicians. While some particles can come...
